Why Is PRECIGEN INC (PGEN) Stock Down Today?

Precigen Inc. shares fell 25.94% to $5.14 on Monday. The sharp decline followed the U.S. Food and Drug Administration approval of Voceryq, a competing respiratory treatment from Inovio Pharmaceuticals.

What Happened

The FDA granted approval to Inovio’s immunotherapy product, creating direct competitive pressure for Precigen’s pipeline. This regulatory milestone for a rival firm triggered a significant sell-off in PGEN shares. The move occurred ahead of Precigen’s scheduled earnings release.

Innovio Pharmaceuticals shares rose more than 230% in the premarket session following the news. The divergence highlighted the market’s reaction to the new competitor entering the respiratory treatment space. Precigen’s stock had already been under pressure, dropping 19.6% over the previous eight sessions from $6.39 to $5.14.

What The Data Shows

Precigen has a market capitalization of $2.5 billion and remains unprofitable with a trailing twelve-month EPS of -$0.98. Revenue grew 1875.0% year-over-year, but the company posted a net margin of -184.0%. The stock trades within a 52-week range of $3.04 to $8.98.

Recent insider activity shows a net selling trend. In the last 90 days, insiders executed four sells totaling $2.6 million against one buy of $25,000. Director Jeffrey B. Kindler sold shares on August 26, 2026, while Chief Commercial Officer Phil Tennant sold on August 25, 2026. COO Rutul R. Shah sold on August 21, 2026. The most recent filing was dated August 28, 2026.

Retail sentiment on Stocktwits reached a record 94 out of 100, described as extremely bullish, despite the stock’s recent decline. This contrasts with a deteriorating broader sentiment trend, where the 30-day average stood at 42 out of 100 and the last seven days averaged 37 out of 100.

What To Watch

Precigen is approaching its earnings release on Wednesday. Investors will monitor how management addresses the competitive landscape following the FDA approval of Inovio’s Voceryq. The company’s ability to maintain its revenue growth trajectory against a newly approved rival will be a key focus for the coming quarter.